|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Regulation: OK After All
Author(s)Kevin Gopal
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Advertisement
Articles in this issue
about 25 years ago
Internet DTC - Minding Your P's & Q'sabout 25 years ago
Regulation: Two-Track Planabout 25 years ago
Policy: Tectonic Shiftabout 25 years ago
Liberated?about 25 years ago
A Matter of Tasteabout 25 years ago
Partnerships: Bargaining Biotechsabout 25 years ago
Pediatric Mandateabout 25 years ago
Genentech's Passion for PatientsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
2
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
3
What Unexpected Costs do GLP-1 Patients Face?
4
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
5